×
×

Meeting on IGA Nephropathy

The National Kidney Foundation’s and IgA Nephropathy Foundation’s patient focused drug development (EL-PFDD) meeting on IgA Nephropathy was held on August 19, 2019.  Click here to go to the NKF Meeting Recording.

 

About EL-PFDD Meetings

Externally-led Patient-focused Drug Development (EL-PFDD) meetings bring together patients and their care-partners, representatives from the Food and Drug Administration (FDA), pharmaceutical companies interested in developing drugs for the disease, and doctors who are experts in the particular disease- all to hear from patients about the disease in question. In these meetings, the patient’s experience is brought to the forefront for the FDA and pharmaceutical companies to understand. “Externally-led” refers to PFDD meetings that are led by organizations outside of the FDA.

References

  • Hall, Y.N., Fuentes, E.F., Chertow, G.M. et al. Race/ethnicity and disease severity in IgA nephropathy. BMC Nephrol 5, 10 (2004). https://doi.org/10.1186/1471-2369-5-10
  • Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, et al. (2012) Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLoS Genet 8(6): e1002765. doi:10.1371/journal.pgen.1002765